IRCT138901292641N2已完成4 期
Etanercept Versus Placebo in Ocular Manifestations of Behcet's Disease, a single Blind Controlled trial
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16 years 至 70 years（—）
- 性别
- All
入选标准
- •Inclusion Criteria: Behcet's Disease according to the International Criteria for Behcet's disease (ICBD), Active posterior uveitis and/or retinal vasculitis
排除标准
- •Visual acuity inferior to 1/10 on Snellen chart, Being under cytotoxic drugs or having received them in the past 2 months, Not being able to follow the one year treatment and the regular follow ups
研究者
相似试验
Unknown
不适用
Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's DiseaseUveal DiseaseBehcet SyndromeNCT00931957Tehran University of Medical Sciences80
已完成
3 期
Comparison, effect of Ophthalmic ointment tetracycline1% and erythromycin 0.5% in prophylaxis of ophthalmia Neonatorum.Condition 1: neonatal conjunctivitis. Condition 2: Gonococcal conjunctivitis.Gonococcal infection of eyeNeonatal conjunctivitisIRCT201101295714N1niversity of Medical Sciences Vice chancellor for research, Kordistan330
已完成
不适用
Efficacy of Aflibercept for macular edema in our hospitaldiabetic macular edema, retinal vein occlusionJPRN-UMIN000048108Chiba University300
已完成
3 期
A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry EyeDry EyeNCT05109702HanAll BioPharma Co., Ltd.260
暂停
3 期
A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye DiseaseDry EyeNCT06400589HanAll BioPharma Co., Ltd.750